Trial evaluates recombinant GM-CSF for improving outcomes in autoimmune pulmonary alveolar proteinosis, indicating potential for new therapies.
The author describes the scientific foundations of the IMPALA-2 trial, in which a recombinant GM-CSF was evaluated for treatment of autoimmune pulmonary alveolar proteinosis.
No takes yet. Share an insight, caveat, or question.
John F. Seymour (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: